Biological and Pharmaceutical Bulletin
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 18,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Ken-ichi Hosoya
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama

Read more
9,786 registered articles
(updated on April 21, 2019)
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
Featured article
Volume 42 (2019) Issue 3 Pages 448-452
Class IIb HDAC Inhibition Enhances the Inhibitory Effect of Am80, a Synthetic Retinoid, in Prostate Cancer Read more
Editor’s picks

The growth-inhibitory effects of Am80 (tamibarotene), a specific retinoic acid receptor (RAR) α/β agonist, in combination with a histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA) on androgen receptor positive or negative prostate cancer cell lines were investigated. Ishigami-Yuasa et al. found that the combination therapy of Am80 and SAHA showed an enhanced growth-inhibitory effect on LNCaP cells. Studies with various HDAC isotype-selective inhibitors indicated that the Class IIb HDACs, especially HDAC6, had significant roles in the enhanced effect of the combination. Thus, dual targeting of Class IIb HDAC and RARα would be useful therapeutic strategy for prostate cancer.

View the past featured articles
View all articles in Current issue
Most viewed articles Mar.2019
Share this page
Select past volume & issue
Journal news & Announcements
  • Biol. Pharm. Bull. Vol. 42 No. 4
    Current Topics: Inflammation and Tissue Remodeling as Potential Therapeutic Targets

  • Biol. Pharm. Bull. Vol. 42 No. 3
    Current Topics Drug Discovery: Recent Progress and the Future